Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures

EMERYVILLE, Calif.: EMERYVILLE, Calif., Jan. 26, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company's founding investors...

Click to view original post